Joseph P. Erinjeri, MD PhD

Attending
Memorial Sloan Kettering Cancer Center, United States

Presentation(s):

• Improved Local Control at the Cost of Reduced Lymphocyte Count: A Propensity Score-Matched Analysis of Yttrium-90 Radioembolization versus Hepatic Arterial Embolization for Hepatic Metastatic Melanoma

  Monday, March 31, 2025
  3:27 PM – 3:36 PM CT

• From Polymers to Patients: Hydrogels for the Treatment of Hepatocellular Carcinoma

  Monday, March 31, 2025
  5:15 PM – 5:20 PM CT

• Outcomes by key prognostic factors in EMERALD-1: a Phase 3 study of durvalumab ± bevacizumab with transarterial chemoembolization (TACE) in participants with embolization-eligible unresectable hepatocellular carcinoma (uHCC)

  Tuesday, April 1, 2025
  4:03 PM – 4:12 PM CT

• SF3B1 and BAP1 Mutations Predict Survival Outcomes in Metastatic Uveal Melanoma Treated with Hepatic Artery Embolization

  Tuesday, April 1, 2025
  3:45 PM – 3:54 PM CT